De-Implementation of Ineffective or Low-value Clinical Practices along the Cancer Care Continuum

NOT-CA-20-021
Notice of Special Interest (NOSI)
Pre-Application Funding Webinar
National Cancer Institute

January 22, 2020
Using WebEx and Webinar Training Logistics

- All lines will be in listen-only mode
- Submit questions at any time during the presentation. Type into the Q&A Panel and select Host
- A moderator will ask the question on your behalf during the Q&A portions of the webinar
- This webinar is being recorded and will be posted at a later date
Webinar Presenters

Erica S. Breslau, PhD, MPH
Program Director
Health Systems and Interventions Research Branch
Healthcare Delivery Research Program
Division of Cancer Control and Population Sciences
breslaue@mail.nih.gov

Wynne E. Norton, PhD
Program Director
Implementation Science
Division of Cancer Control and Population Sciences
wynne.norton@nih.gov
Webinar Overview

1. Overview of NIH Notice of Special Interest (NOSI)

2. Background, Purpose of NCI De-implementation NOSI, [NOT-CA-20-021](#)

3. Research Objectives, Select Research Areas

4. Application and Submission Information

5. Questions
NIH Notice of Special Interest (NOSI)

- Notice posted in the NIH guide that institutes and centers can use to share and update research priorities.

- NOSIs succinctly highlight a specific topic of interest (e.g., specific area of research or program).

- NOSIs direct applicants to one or more active FOAs for submission of applications for the initiative described.

- NOSIs: Standing study section, no set-aside funds, NOSIs slowly replacing program announcements (PAs).

- See [NOT-OD-19-107](#) and [FAQs](#) for details on NIH NOSIs.
NCI De-Implementation NOSI

- **NOT-CA-20-021**
- De-implementation of Ineffective or Low-value Clinical Practices along the Cancer Care Continuum
- Issued January 6th, 2020
- **Only** allows for applications that use R01 mechanism
- **Only** supported by NCI
- **Definition**: De-implementation research is broadly defined as the scientific study of factors, processes, and strategies for reducing, replacing, or stopping the use of ineffective or low-value clinical practices in healthcare delivery settings.
Background

- Use of ineffective or low-value clinical practices may have negative impact on patients, healthcare providers, healthcare teams, healthcare organizations, and healthcare systems.

- Ineffective or low-value cancer-related practices are common along cancer care continuum.

- Research on de-implementation of ineffective or low-value practices is understudied.

- A better understanding of de-implementation is necessary to optimize patient health outcomes and maximize use of limited resources.
Purpose

- Highlight interest in investigator-initiated grant applications that propose to study the de-implementation of ineffective or low-value clinical practices, programs, treatments, or interventions (“practices”) along the cancer care continuum from detection to end-of-life.

- Studies should propose to use rigorous methods and study designs to understand and/or affect de-implementation of ineffective or low-value clinical practices in cancer care.
Research Objectives

- Broaden and deepen scientific understanding of de-implementation.
- Exploratory and/or hypothesis-driven R01 studies.
- Variety of study designs (e.g., observational, experimental, quasi-experimental, natural experiments, pragmatic randomized clinical trials).
- Variety of research methods (e.g., qualitative, quantitative, mixed methods).
- Studies must focus on one or more phases of the cancer care continuum: detection, diagnosis, treatment, survivorship, and/or end-of-life.
- Studies are encouraged to examine multilevel aspects of de-implementation.
Select Research Areas

- Research encouraged through this NOSI includes (but is not limited to) studies that propose to:
  - Explore multilevel factors associated with de-implementation.
  - Understand de-implementation predictors, processes, and outcomes.
  - Understand how de-implementation may differ by type of ineffective or low-value clinical practice, phase along cancer care continuum, or type of action.
  - Develop and validate instruments to measure de-implementation.
  - Develop and test multilevel strategies to facilitate de-implementation.
Application Process

- De-implementation of Ineffective or Low-value Clinical Practices along the Cancer Care Continuum, [NOT-CA-20-021](#)

- Must submit application to one of four R01 funding opportunity announcements (FOAs) listed in the de-implementation NOSI announcement:
  - [PAR-18-869](#)
  - [PAR-18-559](#)
  - [PAR-19-274](#)
  - [PA-19-056](#)

- Applications in response to this NOSI cannot be submitted to other grant mechanisms (e.g., R21, R03) or FOAs not listed above.
<table>
<thead>
<tr>
<th>Activity Code</th>
<th>FOA Number</th>
<th>FOA Title</th>
<th>First Available Due Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>R01</td>
<td><strong>PAR-18-869</strong></td>
<td>Modular R01s in Cancer Control and Population Sciences R01 Clinical Trial <em>Optional</em></td>
<td>March 6&lt;sup&gt;th&lt;/sup&gt;, 2020</td>
</tr>
<tr>
<td>R01</td>
<td><strong>PAR-18-559</strong></td>
<td>Cancer Prevention and Control Clinical Trials Grant Program R01 Clinical Trial <em>Required</em></td>
<td>June 5&lt;sup&gt;th&lt;/sup&gt;, 2020</td>
</tr>
<tr>
<td>R01</td>
<td><strong>PAR-19-274</strong></td>
<td>Dissemination and Implementation Research in Health R01 Clinical Trial <em>Optional</em></td>
<td>June 5&lt;sup&gt;th&lt;/sup&gt;, 2020</td>
</tr>
<tr>
<td>R01</td>
<td><strong>PA-19-056</strong></td>
<td>NIH Research Project Grant Parent R01 Clinical Trial <em>Not Allowed</em></td>
<td>June 5&lt;sup&gt;th&lt;/sup&gt;, 2020</td>
</tr>
</tbody>
</table>
Application Process: Important Dates

- NOSI expiration date: May 10th, 2022
- Earliest submission date: March 6th, 2020 (PAR-18-869 only)
- Application due dates:
  - PAR-18-869 See notice for due dates
  - PAR-18-559 Standard application due dates
  - PAR-19-274 Standard application due dates
  - PA-19-056 Standard application due dates
- Applicants may submit to any of the reissuances of above announcements through NOSI expiration date.
Application Requirements

- All instructions in the SF424 (R&R) application guide and the FOA used for submission must be followed.

- Applicants must include “NOT-CA-20-021” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form.

- Applications without the correct Agency Routing Identifier information will not be considered for the NOSI initiative.

- Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.
Review Criteria

- Standard review criteria as described in eligible R01 FOAs.

- **Scored review criteria**: Significance, Innovation, Investigators, Approach, Environment.

- **Additional review criteria**: Study timeline (for clinical trials), protections for human subjects, inclusion, vertebrate animals, biohazards.

- **Additional review considerations**: Check FOA to see resource sharing plan requirements (e.g., data sharing plan) or other listed requirements.
Common Question #1

- Where can I find more information about NIH NOSIs?

- NOT-OD-19-107, NIH Expanding Usage of Notices of Special Interest (NOSI). Issued by NIH, June 14\textsuperscript{th}, 2019.

- NIH NOSI FAQs: What is a NOSI? How does NIH distinguish applications submitted in direct response to an FOA from applications submitted in response to a NOSI that uses that FOA for submission? Can I include an assignment request when I submit my application to a NOSI?
Common Question #2

- **What is the cancer care continuum and how does that relate to my application?**

- For purposes of this NOSI, the cancer care continuum includes the following phases: detection, diagnosis, treatment, survivorship, and end-of-life care.

- Applications must focus on one or more phases of the cancer care continuum listed above.

- Applications that focus on other aspects of the cancer continuum (e.g., etiology, prevention) are considered non-responsive to this NOSI.
Common Question #3

- **What are clinical practices?**

- For purposes of this NOSI, clinical practices are practices, programs, treatments, or interventions delivered along the cancer care continuum from detection to end-of-life.
Common Question #4

- What clinical practices along the cancer care continuum are considered to be ineffective or low-value?

- Determination made by research team.

- Application should explain why the proposed clinical practice is considered ineffective or low-value.

- Potential resources for identifying candidate clinical practices:
  - Choosing Wisely® recommendations
  - Clinical practice guidelines
  - Professional society recommendations
Resources

- A recording of this webinar will be posted on our website shortly.


Submission Inquiries

- Scientific/Research Contacts:
  - Erica S. Breslau (HDRP), breslaue@mail.nih.gov
  - Wynne E. Norton (IS), wynne.norton@nih.gov

- Financial/Grants Management Contact:
  - Carol Perry, perryc@mail.nih.gov
Webinar Audience Questions

Please type your question in the Q&A section on WebEx.